Tag: Nasdaq:RPRX
Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys
Royalty Pharma to provide tailored funding solution to enable MorphoSys’ acquisition of Constellation PharmaceuticalsInvestment is anchored by royalties on Janssen’s TremfyaPartnership also includes...
Royalty Pharma Acquires OXLUMO™ Royalty Interest From Dicerna for up to...
Dicerna to receive $180 million upfront and up to $60 million in potential additional milestone payments NEW YORK and LEXINGTON, Mass., April...
Royalty Pharma Acquires Royalty Interest in Cabozantinib From GSK
NEW YORK, April 01, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty...